Last updated on September 2015

Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C


Brief description of study

End stage HCV-related cirrhosis has become a major indication for liver transplantation (LT). Unfortunately, recurrence of HCV infection on the liver graft occurs in almost all patients following transplantation and causes a persistent infection that leads to chronic hepatitis and cirrhosis in a significant proportion of patients. To date there is no effective way to prevent HCV reinfection of the liver graft in the early phase after transplantation. . Early passive immunotherapy with neutralizing antibodies against HCV should be considered for preventing reinfection of liver transplanted patients associated with HCV. This approach is well established in the case of patients undergoing liver transplantation for chronic hepatitis B virus infection. Our purpose is to produce neutralizing monoclonal antibodies to prevent reinfection of the liver graft.

Clinical Study Identifier: NCT00638144

Contact Investigators or Research Sites near you

Start Over

Michel DOFFOEL, MD

Service d'H pato-Gastro-Ent rologie - H pital Civil
Strasbourg, France
1.62miles
  Connect »

Albert FARADJI, MD

Service d'H matologie et Oncologie - H pital de Hautepierre
Strasbourg, France
2.2miles
  Connect »

Philippe WOLF, MD

Service de Chirurgie G n rale et Transplantation Multiorganes - H pital de Hautepierre
Strasbourg, France
2.2miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.